Imipenem + Imipenem
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ventilator Associated Pneumonia
Conditions
Ventilator Associated Pneumonia
Trial Timeline
Nov 1, 2011 → Jul 1, 2014
NCT ID
NCT01379157About Imipenem + Imipenem
Imipenem + Imipenem is a approved stage product being developed by Merck for Ventilator Associated Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT01379157. Target conditions include Ventilator Associated Pneumonia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01379157 | Approved | Completed |
| NCT02213783 | Approved | Completed |
Competing Products
9 competing products in Ventilator Associated Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Doripenem + Imipenem-Cilastatin + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/Tazobactam + Piperacillin/Tazobactam | Merck | Phase 3 | 77 |
| Vancomycin + Linezolid | Pfizer | Approved | 84 |
| anidulafungin | Pfizer | Phase 2 | 51 |
| Linezolid | Pfizer | Pre-clinical | 22 |
| aerosolized vancomycin or gentamicin | Nektar Therapeutics | Phase 2 | 47 |
| IC43 + Placebo | Valneva SE | Phase 2 | 47 |
| Ceftobiprole | Basilea Pharmaceutica | Phase 1 | 28 |